We are analyzing https://link.springer.com/article/10.1186/s13046-016-0478-9.

Title:
FGF19/FGFR4 signaling contributes to the resistance of hepatocellular carcinoma to sorafenib | Journal of Experimental & Clinical Cancer Research
Description:
Background Sorafenib, a multi-kinase inhibitor, is used as a standard therapy for advanced hepatocellular carcinoma (HCC). However, complete remission has not been achieved and the molecular basis of HCC resistance to sorafenib remains largely unknown. Previous studies have shown that fibroblast growth factor 19 (FGF19) expression correlates with tumor progression and poor prognosis of HCC. Here, we demonstrate the novel role of FGF19 in HCC resistance to sorafenib therapy. Methods FGF19 Knockdown cells were achieved by lentiviral-mediated interference, and FGFR4 knockout cells were achieved by CRISPR-Cas9. Protein levels of FGF19, FGFR4 and c-PARP in various HCC cell lines were measured by Western blotting analysis. Cell viability was determined by MTS assay, apoptosis was determined by DAPI nuclear staining and Western blot of c-PRAP, and ROS generation was determined by DCFH-DA staining and electrochemical biosensor. Results We showed that FGF19, when overexpressed, inhibited the effect of sorafenib on ROS generation and apoptosis in HCC. In contrast, loss of FGF19 or its receptor FGFR4 led to a remarkable increase in sorafenib-induced ROS generation and apoptosis. In addition, knockdown of FGF19 in sorafenib-resistant HCC cells significantly enhanced the sensitivity to sorafenib. Importantly, targeting FGF19/FGFR4 axis by ponatinib, a third-generation inhibitor of chronic myeloid leukemia, overcomes HCC resistance of sorafenib by enhancing ROS-associated apoptosis in sorafenib-treated HCC. Conclusion Our results provide the first evidence that inhibition of FGF19/FGFR4 signaling significantly overcomes sorafenib resistance in HCC. Co-treatment of ponatinib and sorafinib may represent an effective therapeutic approach for eradicating HCC.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Science
Education
Telecommunications

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 7,626,432 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We find it hard to spot revenue streams.

Earning money isn't the goal of every website; some are designed to offer support or promote social causes. People have different reasons for creating websites. This might be one such reason. Link.springer.com might be plotting its profit, but the way they're doing it isn't detectable yet.

Keywords {🔍}

sorafenib, cells, fgf, hcc, cell, apoptosis, article, determined, ros, generation, pubmed, google, scholar, fgfr, hepatocellular, carcinoma, cancer, resistance, fig, cas, staining, mhcch, signaling, sorafenibresistant, expression, viability, electrochemical, effect, ponatinib, treatment, fgffgfr, knockdown, levels, dapi, sorafenibinduced, additional, dcfhda, treated, file, figure, sora, growth, patients, oxidative, assays, hepg, analysis, data, shown, factor,

Topics {✒️}

gsk3beta/beta-catenin signaling cascade fibroblast growth factor article download pdf brunner-la rocca hp raf/mek/erk signaling raf/mek/erk pathway fgf19/fgfr4 signaling contributes generate sorafenib-resistant cells targeting fgf19/fgfr4 pathway targeting fgf19/fgfr4 axis molecularly targeted therapeutics 4′-6-diamidino-2-phenylindole dcfh-da blocking fgf19/fgfr4 signaling sorafenib-induced oxidative stress hbx-induced cell migration blocking fgf19/fgfr4 axis additive anti-cancer effects improve anti-cancer effects high-level amplification frequency sorafenib-resistant cells exposed cancer cells based sorafenib-resistant hcc cells sorafenib-induced cell response sorafenib-resistant mhcc97h cells cell growth/survival sora-resistant hcc cells crispr-cas9 sorafenib-induced cell viability related subjects sorafenib-induced cell apoptosis reactive oxygen species hepatocellular carcinoma cells sorafenib-induced high levels sorafenib-resistant cells compared sorafenib-resistant hepg2 cells advanced hepatocellular carcinoma sorafenib-induced cell phenotypes ros-sensitive signaling pathways decreased cell proliferation yt performed research fgf19/fgfr4 signaling inhibition stemness-related properties receptor tyrosine kinases hepatocellular carcinoma incidence hepatocellular carcinoma pathogenesis hepatocellular carcinoma progression sorafenib-induced ros generation privacy choices/manage cookies yt designed research sora-induced ros generation

Schema {🗺️}

WebPage:
      mainEntity:
         headline:FGF19/FGFR4 signaling contributes to the resistance of hepatocellular carcinoma to sorafenib
         description:Sorafenib, a multi-kinase inhibitor, is used as a standard therapy for advanced hepatocellular carcinoma (HCC). However, complete remission has not been achieved and the molecular basis of HCC resistance to sorafenib remains largely unknown. Previous studies have shown that fibroblast growth factor 19 (FGF19) expression correlates with tumor progression and poor prognosis of HCC. Here, we demonstrate the novel role of FGF19 in HCC resistance to sorafenib therapy. FGF19 Knockdown cells were achieved by lentiviral-mediated interference, and FGFR4 knockout cells were achieved by CRISPR-Cas9. Protein levels of FGF19, FGFR4 and c-PARP in various HCC cell lines were measured by Western blotting analysis. Cell viability was determined by MTS assay, apoptosis was determined by DAPI nuclear staining and Western blot of c-PRAP, and ROS generation was determined by DCFH-DA staining and electrochemical biosensor. We showed that FGF19, when overexpressed, inhibited the effect of sorafenib on ROS generation and apoptosis in HCC. In contrast, loss of FGF19 or its receptor FGFR4 led to a remarkable increase in sorafenib-induced ROS generation and apoptosis. In addition, knockdown of FGF19 in sorafenib-resistant HCC cells significantly enhanced the sensitivity to sorafenib. Importantly, targeting FGF19/FGFR4 axis by ponatinib, a third-generation inhibitor of chronic myeloid leukemia, overcomes HCC resistance of sorafenib by enhancing ROS-associated apoptosis in sorafenib-treated HCC. Our results provide the first evidence that inhibition of FGF19/FGFR4 signaling significantly overcomes sorafenib resistance in HCC. Co-treatment of ponatinib and sorafinib may represent an effective therapeutic approach for eradicating HCC.
         datePublished:2017-01-09T00:00:00Z
         dateModified:2017-01-09T00:00:00Z
         pageStart:1
         pageEnd:10
         license:http://creativecommons.org/publicdomain/zero/1.0/
         sameAs:https://doi.org/10.1186/s13046-016-0478-9
         keywords:
            FGF19
            FGFR4
            Hepatocellular carcinoma
            Drug resistance
            Sorafenib
            Synergistic effect
            Cancer Research
            Immunology
            Apoptosis
            Oncology
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs13046-016-0478-9/MediaObjects/13046_2016_478_Fig1_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs13046-016-0478-9/MediaObjects/13046_2016_478_Fig2_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs13046-016-0478-9/MediaObjects/13046_2016_478_Fig3_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs13046-016-0478-9/MediaObjects/13046_2016_478_Fig4_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs13046-016-0478-9/MediaObjects/13046_2016_478_Fig5_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs13046-016-0478-9/MediaObjects/13046_2016_478_Fig6_HTML.gif
         isPartOf:
            name:Journal of Experimental & Clinical Cancer Research
            issn:
               1756-9966
            volumeNumber:36
            type:
               Periodical
               PublicationVolume
         publisher:
            name:BioMed Central
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Lixia Gao
               affiliation:
                     name:Augusta University
                     address:
                        name:Department of Oral Biology, Dental College of Georgia, Augusta University, Augusta, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Xuli Wang
               affiliation:
                     name:University of Utah
                     address:
                        name:Department of Radiology and Imaging Sciences, School of Medicine, University of Utah, Salt Lake City, USA
                        type:PostalAddress
                     type:Organization
                     name:University of Utah
                     address:
                        name:Experimental Therapeutics Program, Huntsman Cancer Institute, University of Utah, Salt Lake City, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Yaoliang Tang
               affiliation:
                     name:Augusta University
                     address:
                        name:Vascular Biology Center, Department of Medicine, Medical College of Georgia, Augusta University, Augusta, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Shuang Huang
               affiliation:
                     name:University of Florida College of Medicine
                     address:
                        name:Department of Anatomy and Cell Biology, University of Florida College of Medicine, Gainesville, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Chien-An Andy Hu
               affiliation:
                     name:University of New Mexico School of Medicine
                     address:
                        name:Department of Biochemistry and Molecular Biology, University of New Mexico School of Medicine, Albuquerque, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Yong Teng
               affiliation:
                     name:Augusta University
                     address:
                        name:Department of Oral Biology, Dental College of Georgia, Augusta University, Augusta, USA
                        type:PostalAddress
                     type:Organization
                     name:Augusta University
                     address:
                        name:Department of Biochemistry and Molecular Biology, Medical College of Georgia, Augusta University, Augusta, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:FGF19/FGFR4 signaling contributes to the resistance of hepatocellular carcinoma to sorafenib
      description:Sorafenib, a multi-kinase inhibitor, is used as a standard therapy for advanced hepatocellular carcinoma (HCC). However, complete remission has not been achieved and the molecular basis of HCC resistance to sorafenib remains largely unknown. Previous studies have shown that fibroblast growth factor 19 (FGF19) expression correlates with tumor progression and poor prognosis of HCC. Here, we demonstrate the novel role of FGF19 in HCC resistance to sorafenib therapy. FGF19 Knockdown cells were achieved by lentiviral-mediated interference, and FGFR4 knockout cells were achieved by CRISPR-Cas9. Protein levels of FGF19, FGFR4 and c-PARP in various HCC cell lines were measured by Western blotting analysis. Cell viability was determined by MTS assay, apoptosis was determined by DAPI nuclear staining and Western blot of c-PRAP, and ROS generation was determined by DCFH-DA staining and electrochemical biosensor. We showed that FGF19, when overexpressed, inhibited the effect of sorafenib on ROS generation and apoptosis in HCC. In contrast, loss of FGF19 or its receptor FGFR4 led to a remarkable increase in sorafenib-induced ROS generation and apoptosis. In addition, knockdown of FGF19 in sorafenib-resistant HCC cells significantly enhanced the sensitivity to sorafenib. Importantly, targeting FGF19/FGFR4 axis by ponatinib, a third-generation inhibitor of chronic myeloid leukemia, overcomes HCC resistance of sorafenib by enhancing ROS-associated apoptosis in sorafenib-treated HCC. Our results provide the first evidence that inhibition of FGF19/FGFR4 signaling significantly overcomes sorafenib resistance in HCC. Co-treatment of ponatinib and sorafinib may represent an effective therapeutic approach for eradicating HCC.
      datePublished:2017-01-09T00:00:00Z
      dateModified:2017-01-09T00:00:00Z
      pageStart:1
      pageEnd:10
      license:http://creativecommons.org/publicdomain/zero/1.0/
      sameAs:https://doi.org/10.1186/s13046-016-0478-9
      keywords:
         FGF19
         FGFR4
         Hepatocellular carcinoma
         Drug resistance
         Sorafenib
         Synergistic effect
         Cancer Research
         Immunology
         Apoptosis
         Oncology
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs13046-016-0478-9/MediaObjects/13046_2016_478_Fig1_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs13046-016-0478-9/MediaObjects/13046_2016_478_Fig2_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs13046-016-0478-9/MediaObjects/13046_2016_478_Fig3_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs13046-016-0478-9/MediaObjects/13046_2016_478_Fig4_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs13046-016-0478-9/MediaObjects/13046_2016_478_Fig5_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs13046-016-0478-9/MediaObjects/13046_2016_478_Fig6_HTML.gif
      isPartOf:
         name:Journal of Experimental & Clinical Cancer Research
         issn:
            1756-9966
         volumeNumber:36
         type:
            Periodical
            PublicationVolume
      publisher:
         name:BioMed Central
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Lixia Gao
            affiliation:
                  name:Augusta University
                  address:
                     name:Department of Oral Biology, Dental College of Georgia, Augusta University, Augusta, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Xuli Wang
            affiliation:
                  name:University of Utah
                  address:
                     name:Department of Radiology and Imaging Sciences, School of Medicine, University of Utah, Salt Lake City, USA
                     type:PostalAddress
                  type:Organization
                  name:University of Utah
                  address:
                     name:Experimental Therapeutics Program, Huntsman Cancer Institute, University of Utah, Salt Lake City, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Yaoliang Tang
            affiliation:
                  name:Augusta University
                  address:
                     name:Vascular Biology Center, Department of Medicine, Medical College of Georgia, Augusta University, Augusta, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Shuang Huang
            affiliation:
                  name:University of Florida College of Medicine
                  address:
                     name:Department of Anatomy and Cell Biology, University of Florida College of Medicine, Gainesville, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Chien-An Andy Hu
            affiliation:
                  name:University of New Mexico School of Medicine
                  address:
                     name:Department of Biochemistry and Molecular Biology, University of New Mexico School of Medicine, Albuquerque, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Yong Teng
            affiliation:
                  name:Augusta University
                  address:
                     name:Department of Oral Biology, Dental College of Georgia, Augusta University, Augusta, USA
                     type:PostalAddress
                  type:Organization
                  name:Augusta University
                  address:
                     name:Department of Biochemistry and Molecular Biology, Medical College of Georgia, Augusta University, Augusta, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:Journal of Experimental & Clinical Cancer Research
      issn:
         1756-9966
      volumeNumber:36
Organization:
      name:BioMed Central
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Augusta University
      address:
         name:Department of Oral Biology, Dental College of Georgia, Augusta University, Augusta, USA
         type:PostalAddress
      name:University of Utah
      address:
         name:Department of Radiology and Imaging Sciences, School of Medicine, University of Utah, Salt Lake City, USA
         type:PostalAddress
      name:University of Utah
      address:
         name:Experimental Therapeutics Program, Huntsman Cancer Institute, University of Utah, Salt Lake City, USA
         type:PostalAddress
      name:Augusta University
      address:
         name:Vascular Biology Center, Department of Medicine, Medical College of Georgia, Augusta University, Augusta, USA
         type:PostalAddress
      name:University of Florida College of Medicine
      address:
         name:Department of Anatomy and Cell Biology, University of Florida College of Medicine, Gainesville, USA
         type:PostalAddress
      name:University of New Mexico School of Medicine
      address:
         name:Department of Biochemistry and Molecular Biology, University of New Mexico School of Medicine, Albuquerque, USA
         type:PostalAddress
      name:Augusta University
      address:
         name:Department of Oral Biology, Dental College of Georgia, Augusta University, Augusta, USA
         type:PostalAddress
      name:Augusta University
      address:
         name:Department of Biochemistry and Molecular Biology, Medical College of Georgia, Augusta University, Augusta, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Lixia Gao
      affiliation:
            name:Augusta University
            address:
               name:Department of Oral Biology, Dental College of Georgia, Augusta University, Augusta, USA
               type:PostalAddress
            type:Organization
      name:Xuli Wang
      affiliation:
            name:University of Utah
            address:
               name:Department of Radiology and Imaging Sciences, School of Medicine, University of Utah, Salt Lake City, USA
               type:PostalAddress
            type:Organization
            name:University of Utah
            address:
               name:Experimental Therapeutics Program, Huntsman Cancer Institute, University of Utah, Salt Lake City, USA
               type:PostalAddress
            type:Organization
      name:Yaoliang Tang
      affiliation:
            name:Augusta University
            address:
               name:Vascular Biology Center, Department of Medicine, Medical College of Georgia, Augusta University, Augusta, USA
               type:PostalAddress
            type:Organization
      name:Shuang Huang
      affiliation:
            name:University of Florida College of Medicine
            address:
               name:Department of Anatomy and Cell Biology, University of Florida College of Medicine, Gainesville, USA
               type:PostalAddress
            type:Organization
      name:Chien-An Andy Hu
      affiliation:
            name:University of New Mexico School of Medicine
            address:
               name:Department of Biochemistry and Molecular Biology, University of New Mexico School of Medicine, Albuquerque, USA
               type:PostalAddress
            type:Organization
      name:Yong Teng
      affiliation:
            name:Augusta University
            address:
               name:Department of Oral Biology, Dental College of Georgia, Augusta University, Augusta, USA
               type:PostalAddress
            type:Organization
            name:Augusta University
            address:
               name:Department of Biochemistry and Molecular Biology, Medical College of Georgia, Augusta University, Augusta, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Department of Oral Biology, Dental College of Georgia, Augusta University, Augusta, USA
      name:Department of Radiology and Imaging Sciences, School of Medicine, University of Utah, Salt Lake City, USA
      name:Experimental Therapeutics Program, Huntsman Cancer Institute, University of Utah, Salt Lake City, USA
      name:Vascular Biology Center, Department of Medicine, Medical College of Georgia, Augusta University, Augusta, USA
      name:Department of Anatomy and Cell Biology, University of Florida College of Medicine, Gainesville, USA
      name:Department of Biochemistry and Molecular Biology, University of New Mexico School of Medicine, Albuquerque, USA
      name:Department of Oral Biology, Dental College of Georgia, Augusta University, Augusta, USA
      name:Department of Biochemistry and Molecular Biology, Medical College of Georgia, Augusta University, Augusta, USA

External Links {🔗}(156)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

5.15s.

LINK . SPRINGER . COM {}